



PATENT
ATTORNEY DOCKET NO. 50402/002002

Certificate of Mailing: Date of Deposit: Oct 9, 2008

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Gregory Harnett
Printed name of person mailing correspondence

Gregory Harnett
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	John Nieland et al.	Confirmation No.:	6391
Serial No.:	10/528,308	Art Unit:	1618
Filed:	September 12, 2005	Examiner:	Westerberg, N.M.
		Customer No.:	21559
Title:	INHIBITORS OF THE FATTY ACID OXIDATION FOR THE PROPHYLAXIS AND/OR TREATMENT OF CHRONIC AND/OR ATOPIC SKIN DISEASES		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


DECLARATION OF JOHN NIELAND UNDER 37 C.F.R. § 1.132
TRAVERSING GROUNDS OF REJECTION

Under 37 C.F.R. § 1.132 and regarding the rejection of claims 1, 16, 17, and 20-22 in view of Marshall et al., U.S. Patent No. 4,933,365 ("Marshall"), I declare:

1. I am an inventor of the subject matter that is described and claimed in the above-captioned patent application.
2. I have personal knowledge that etomoxir has been tested as a possible inhibitor of the PLA₂ enzyme, and experimental data indicated that etomoxir showed no significant inhibition of PLA₂ activity.

3. All statements made herein of my own knowledge are true and all statements made on information and belief are believed to be true; and further these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

6 Oct. 2008
Date


Dr. John Nieland